Abstract: A method for determining whether a Systemic lupus erythematosus (SLE) patient is undergoing a pre-flare event, the method comprising obtaining a blood, serum, plasma, or saliva sample from the SLE patient; assessing a level of expression for each of a plurality of biomarkers, the plurality of biomarkers comprising OPN, MCP-1/CCL2, MCP-3/CCL7, IL-17A, TNFRII, TNFRI, IL-4, IL-5, BLyS, TNF?, and IL-7; determining a Lupus Flare Risk Prediction Index (LFPI) for the patient based upon the level of expression for each of a plurality of biomarkers; and based upon the LFPI, determining whether the patient is undergoing a pre-flare event.
Type:
Application
Filed:
July 21, 2021
Publication date:
January 11, 2024
Applicants:
Progentec Diagnostics, Inc., Oklahoma Medical Research Foundation
Abstract: The present disclosure relates to compositions of N-acetylcysteine for use in treating aortic stenosis. Methods of treating aortic stenosis in a subject comprising administering to said subject an effective amount of N-acetylecysteine (NAC) or other thiol-reactive compound, or agents that inhibit TGF-Beta activation and/or signaling.
Abstract: Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-? (IFN-?) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-?) or one or more alternative therapies with or without IFN-?.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
August 29, 2023
Assignees:
OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.
Type:
Application
Filed:
September 16, 2022
Publication date:
August 24, 2023
Applicants:
Oklahoma Medical Research Foundation, Oklahoma Medical Research Foundation
Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.
Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.
Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.
Abstract: Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).
Type:
Application
Filed:
March 4, 2022
Publication date:
December 1, 2022
Applicants:
Laboratory Corporation of America Holdings, Oklahoma Medical Research Foundation
Inventors:
Guy L. Cavet, Yijing Shen, Nicholas Knowlton, Michael Centola
Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Type:
Grant
Filed:
January 31, 2019
Date of Patent:
October 4, 2022
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Charles T. Esmon, Jun Xu, Xiaomei Zhang
Abstract: Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
April 12, 2022
Assignees:
Laboratory Corporation of America Holdings, Oklahoma Medical Research Foundation
Inventors:
Guy L. Cavet, Yijing Shen, Nicholas Knowlton, Michael Centola
Abstract: The present disclosure describes the use peptides of comprising ubiquitin interacting motifs (UIMs) alone or in combination with other agents to treat conditions such as cancer, atherosclerosis and obesity.
Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.
Type:
Grant
Filed:
November 15, 2016
Date of Patent:
August 3, 2021
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
Inventors:
Xiao-Yan Zhao, Andreas Wilmen, Christoph Freiberg, Lars Linden, Ji-Yun Kim, Subramanian Yegneswaran, Karin Regnstrom, Ursula Egner, Xinquan Wang
Abstract: The present disclosure relates to compositions of N-acetylcysteine for use in treating aortic stenosis. Methods of treating aortic stenosis in a subject comprising administering to said subject an effective amount of N-acetylecysteine (NAC) or other thiol-reactive compound, or agents that inhibit TGF-Beta activation and/or signaling.
Abstract: A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.
Abstract: The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.
Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
February 11, 2020
Assignees:
Hough Ear Institute, Oklahoma Medical Research Foundation
Abstract: The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject.
Abstract: Compounds having inhibitory activity against retinaldehyde dehydrogenases (RALDHs). The compounds can be used, for example, to inhibit synthesis of retinoic acid for the treatment of refractive error disorders such as myopia, and as infertility treatments by inhibiting spermatogenesis.
Type:
Grant
Filed:
September 16, 2016
Date of Patent:
December 31, 2019
Assignees:
The Board of Regents of the University of Oklahoma, Oklahoma Medical Research Foundation
Inventors:
Jody A. Summers, Angelica R. Harper, Tim Mather, Anthony Burgett, Anh Thi Quynh Le
Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.